8-K: Splash Beverage Group Licenses CannEpil for Epilepsy Treatment

Splash Beverage Group secures exclusive worldwide rights to CannEpil, a cannabinoid formulation for drug-resistant epilepsy, through a new license agreement with Argent Biopharma.

Summary

• Splash Beverage Group, Inc. has entered into an Exclusive License Agreement with Argent Biopharma Limited (RGT) to acquire worldwide rights for the pharmaceutical product CannEpil.
• CannEpil is a compounded isolated cannabinoid formulation of CBD and THC isolates in a liquid solution, developed by RGT for the treatment of drug-resistant epilepsy and related neurological conditions.
• The agreement includes a 15% royalty payment to Argent Biopharma on net revenue generated from CannEpil sales.
• Splash Beverage Group is committed to initiating Phase I clinical trials within 24 months and Phase II trials within 48 months, with a New Drug Application (NDA) filing targeted after successful trials.
• As part of the consideration, Splash Beverage Group will issue 5,500 shares of Series D Convertible Preferred Stock, with a stated value of $1,000 per share ($5.5 million total), to Mercer Street Global Opportunity Fund, LLC, in exchange for the cancellation of Argent Biopharma's outstanding promissory notes held by Mercer Street totaling approximately $5.5 million.
• C/M Capital Partners, LP, Splash Beverage Group's equity line of credit provider, has committed to invest at least $1 million to support commercialization efforts.
• The agreement has an initial term of 20 years, with automatic five-year renewals unless terminated.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a significant strategic move into a new, potentially high-growth market with a licensed product. However, the inherent risks of pharmaceutical development, the royalty obligations, and potential dilution temper the overall sentiment.

Positives

• Acquisition of exclusive worldwide rights to CannEpil, a promising pharmaceutical product for drug-resistant epilepsy.
• Potential for significant market penetration in the epilepsy treatment sector.
• Commitment from C/M Capital Partners for a minimum $1 million investment to support commercialization.
• Restructuring of Argent Biopharma's debt through the issuance of Series D Convertible Preferred Stock, strengthening the balance sheet.
• Clear development milestones and timelines established for clinical trials and regulatory submissions.
• Argent Biopharma's existing IND number for CannEpil positions it for potential U.S. market entry.

Negatives

• Significant royalty obligation of 15% on net revenue to Argent Biopharma.
• Requirement to initiate Phase I trials within 24 months and Phase II within 48 months, requiring substantial capital and execution.
• The success of the product is contingent on successful clinical trials and FDA approval, which carry inherent risks.
• The issuance of Series D Convertible Preferred Stock could lead to future dilution for common stockholders.
• The company must negotiate a detailed supply and quality agreement with Argent Biopharma within 90 days.
• Potential for termination of the agreement by Argent Biopharma if development milestones are not met or regulatory approval is not obtained within five years in the U.S.

Risks

• Failure to achieve clinical trial success or obtain regulatory approval for CannEpil.
• Inability to raise sufficient capital to fund clinical development and commercialization efforts.
• Competition from existing or emerging treatments for drug-resistant epilepsy.
• Potential manufacturing or supply chain disruptions.
• Risks associated with the conversion of Series D Preferred Stock into common stock, potentially impacting share price.
• Regulatory hurdles and evolving conditions within the cannabinoid and wellness industries.
• The company's ability to recommence revenue-generating activities with limited staffing.
• Potential for Argent Biopharma to terminate the agreement if development milestones are not met or if regulatory approval is not obtained within five years in the U.S.

Future Outlook

The company aims to initiate Phase I clinical trials within 24 months and Phase II trials within 48 months, followed by an NDA filing. Commercialization efforts will be supported by a minimum $1 million investment from C/M Capital Partners. The license agreement has a 20-year initial term with potential for renewal.

Management Comments

• Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group, certified the adoption of resolutions by the Board of Directors regarding the Series D Convertible Preferred Stock.
• The filing includes a cautionary note regarding forward-looking statements, emphasizing that actual results may differ materially due to various factors, including the success of the license, intellectual property protection, capital raising needs, regulatory compliance, and evolving industry conditions.

Industry Context

StockSavvy.ai notes that this strategic licensing agreement positions Splash Beverage Group to enter the pharmaceutical market with a product targeting a significant unmet medical need in drug-resistant epilepsy. The move into biopharmaceuticals represents a diversification for a company historically associated with beverages, leveraging cannabinoid-based therapeutics.

Comparison to Industry Standards

• The 15% royalty rate on net revenue is within the typical range for pharmaceutical licensing agreements, particularly for early-stage or clinical-stage assets.
• The development timelines (24 months for Phase I, 48 months for Phase II) are standard for biopharmaceutical development, though aggressive for a company new to the sector.
• The $0.25 conversion price for Series D Preferred Stock, with a $0.15 floor, is a common feature in convertible securities, designed to offer downside protection to investors while allowing for potential upside participation.
• The beneficial ownership limitation of 4.99% (or 9.99%) is a standard protective clause in convertible securities to prevent excessive dilution and maintain control for existing shareholders.

Corporate Governance

Related Party Transactions

• The issuance of 5,500 shares of Series D Convertible Preferred Stock to Mercer Street Global Opportunity Fund, LLC, in exchange for the cancellation of Argent Biopharma's debt held by Mercer Street.
• C/M Capital Partners, LP, an affiliate of Splash Beverage Group's equity line of credit provider, is committed to investing at least $1 million and will receive a $1 million sales bonus.

Stakeholder Impact

• Shareholders: Potential for future dilution due to the conversion of Series D Preferred Stock. The success of CannEpil could significantly increase shareholder value.
• Creditors: Argent Biopharma's debt to Mercer Street is being extinguished through the issuance of preferred stock.
• Suppliers: Argent Biopharma will act as the primary manufacturer, subject to negotiation of a supply agreement.
• Management: Increased responsibility for executing clinical trials and navigating pharmaceutical regulatory pathways.

Next Steps

• Negotiate and execute a detailed supply agreement and quality agreement with Argent Biopharma within 90 days.
• Initiate Phase I clinical trials within 24 months.
• Initiate Phase II clinical trials within 48 months.
• File an NDA with the U.S. Food and Drug Administration following successful clinical trials.
• C/M Capital Partners to invest at least $1 million within 60 days.
• Obtain necessary NYSE American approvals for the Series D Convertible Preferred Stock issuance.

Key Dates

Recommendation

The licensing of CannEpil is a significant strategic pivot into the biopharmaceutical sector, offering substantial growth potential if successful. However, the company is still in the early stages of development with considerable execution risk, capital requirements, and regulatory hurdles. The issuance of preferred stock also introduces potential dilution. Therefore, a 'hold' recommendation is appropriate pending further progress in clinical trials and regulatory approvals.

Keywords

Splash Beverage Group, CannEpil, Argent Biopharma, Epilepsy Treatment, Cannabinoid Formulation, License Agreement, Clinical Trials, FDA Approval, Series D Convertible Preferred Stock, Drug-Resistant Epilepsy, Neurological Conditions, Pharmaceutical Product